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Previous studies for treating Patellofemoral Pain Syndrome (PFPS) are
controversial regarding the effectiveness in alleviating anterior knee pain (AKP). The
muscular imbalance between the vastus medialis oblique/vastus lateralis (VMO/VL) may
be the underlying mechanical issue causing PFPS. It is hypothesized that Botox can
decrease the force production capability of the lateral musculature mechanically similar
to surgery.

Strengthening the VMO while using Botox treatment can alleviating the

muscular imbalance that occurs with subjects with PFPS.
A double blind study, having all participants blinded and uninformed of the
injection contents, was implemented to test this hypothesis testing three female subjects.
Four knees were treated. One subject received the Botox treatment and serially a placebo
injection in the other limb. Two other subjects received placebo injections. EMG was
executed to evaluate functional testing and the performance of the injections during
extension exercises. Electromyography (EMG) data were collected from the muscle
groups while the subjects performed forceful knee extension activities on an isokinetic
dynamometer. In addition, kinetic jump data and self-reports of pain and activity were
collected. Data were collected four times during a 12-week period.
The subject who received Botox injections expressed a significant decrease in
reported PFP and an increase in daily activities. Botox was safe and effective in
eliminating anterior knee pain. The VMO and VL resulted in similar fatigue indices at
the completion of the 12- week study. The VMO and VL both resisted fatigue during at
week 12.
This document was created in Microsoft Word 2007.
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Chapter 1: Introduction

A. Overview of Patellofemoral Pain syndrome

Patellofemoral pain syndrome (PFPS) is experienced by over 2.5 million Americans
(Bentz, 2007) and is the leading cause of knee pain in patients under the age of 45. In addition,
patellofemoral pain syndrome (PFPS) dominates knee ailments in regards to overuse injuries.
According to a two-year study completed in 2002 by the University of British Columbia, 46
percent of more than 2,000 runners experienced severe PFP (Scott, 2007). Although the etiology
of PFP remains elusive, strengthening the associated musculature can be effective in reducing
chronic and episodic exacerbations of pain at the patellofemoral joint (PFJ) (Bentz, 2007).
Patellofemoral Pain syndrome is a term commonly used to describe a musculoskeletal
condition that is characterized by anterior knee pain (AKP) (Ng, 2002). The pain is typically
insidious in onset and affects the PFJ. The PFJ is defined as the articulation of the patella with
the femoral condyles of the femur. The patella is part of a joint complex that includes the
tibiofemoral joint and the tibiofubular joint (Ng, 2002). It provides a mobile yet firm site for
ligaments and tendons to attach on the anterior side of the knee.

The patella acts as an

anatomical pulley and provides improved mechanical advantage to the tibiofemoral joint by
increasing the ability of the quadriceps muscles to produce extension torque. The health of the
quadriceps muscle complex is important for proper function of the patellofemoral joint.
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The quadriceps muscle complex consists of the rectus femoris, the vastus lateralis (VL),
vastus intermedius, and vastus medialis (VM). The locations of the muscles of interest and the
patella are illustrated in figure 1.

Figure 1: Right Leg Illustrations for Key Points of Interest

A

B

Figure 1: A. The figure above represents the four muscle groups of the quadriceps
complex. B. Anterior view of the right leg illustrating the location of the muscle
groups and tendon within the patellofemoral joint.
The rectus femoris muscle is the most superficial muscle of the quadriceps muscle
complex. The vastus intermedius muscle is under the rectus femoris muscle and lies between the
lateralis and medialis muscles. The VL lies lateral to the body of the femur (Ng, 2002), while
the VM fibers are positioned medially from the longitudinal axis of the femur. The VM can be
subdivided into the vastus medialis longus (VML) and the vastus medialis oblique (VMO) based
on their fiber orientation. The VML is oriented more vertically similarly with the other rectus
femoral fibers, whereas, the VMO is obliquely oriented at 55° off the longitudinal axis of the
femur, thus distinguishing the muscle group from the other vasti muscles (Farahmand, 1998).
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The fiber orientation of the VML make it better suited to contribute to knee extension torque.
The VMO fiber orientation allows it to play a role in stabilizing the patella during extension
activities.

However in subjects with PFPS, the VMO may be proximally positioned and

abnormally oriented. When the VMO muscles pull vertically in their line of action with the
other rectus femoris muscles the oblique line of pull is reduced. Unlike its vertical oriented
counterparts, the VM is considered to be the weakest and most vulnerable muscle to atrophy of
the extensor mechanism because it is the only quadriceps muscle to have an oblique line of pull;
the position can be affected causing PFPS (Sanchis-Alfonso, 2006). This is a recognized as a
contributing factor in PFP patients with abnormal patellar movement (Ng, 2002 & Vicente,
1993).
Soft tissue structures can also contribute to abnormal patellar movement. These are
tissues include the iliotibial band (ITB). The ITB is a fibrous band whose origin is near the hip,
proximal of the gluteus maximus and minimus muscles. As the band descends, it splits medially
and laterally forming the IT tract. This tract blends with the VL muscle and contributes to lateral
pull on the patella. Excessive lateral pull on the patella can create exacerbate patellofemoral pain
syndrome.
The etiology of PFPS has been reported to transpire with women more than men due to
their anatomical pelvic structure (Sanchis-Alfonso, 2006). Women tend to have a wider pelvis.
This can result in a greater lateral pull on the patella due to the resulting lower extremity
geometry. It is believed that women suffer from PFPS more than men, in part, due to this
geometric difference (Fredericson, 2006). The Q-angle is defined as the biomechanical Q-angle
is defined as the angle between the line of pull from the patellar tendon to the anteriosuperior
iliac spine and the resultant vector from the middle of the patella to the anterior tibial tuberosity
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on the tibia (Fredericson, 2006). The line-of-pull of this muscle group creates an oblique pull
that forms a laterally obtuse angle which is called the quadriceps, or Q, angle as shown in figure
2. The Q angle is normally small, approximately 10-15° in extension and is 0° in flexion when
the femur rotates laterally with respect to the tibia (O’Brein, 2001). The reduction in Q-angle is
associated with a valgus patellar force during quadriceps muscle contraction (Fox, 1993). The
VMO vector forces can counteract the strong VL forces stabilizing the patellofemoral joint.
The patella relies on the balance of the quadriceps muscles and soft tissue structures to
control medial and lateral tracking during the demands of daily activities.

When patellar

movement is compromised, normal activities can lead to shearing and compressive forces that
may contribute to pain (Ng, 2006). Normal walking can produce compressive forces across the
tibiofemoral joint exceeding five times body weight (BW) (O'Brien and Fox, DATES). For the
same activity, forces at the PFJ are only about ½ x BW. However, other common daily activities
increase PFJ forces significantly. Examples include: (1) ascending stairs  PFJ forces equal 1½
x BW, (2) descending stairs  PFJ forces equal 3 x BW, (3) squatting  PFJ forces equal 7.6 x
BW, and (4) jumping  PFJ forces can exceed 20 x BW (Ng, 2002). Inappropriate alignment of
the patella during these activities can strongly influence pain symptoms. Other factors that
reported to contribute to PFP include: tight gastroconemius and quadriceps muscles, delayed
VMO activation, hypermobility of the patella, and decreased power of the quadriceps muscles
(Ng, 2002).
Patellofemoral misalignment and poor patellar tracking have been correlated with PFPS.
Forces produced by the VL muscle may cause lateral patellar tracking and increase compressive
forces under the lateral patellar facet. This weight-bearing facet is already under greater contact
pressure than the medial facet (REF). The line-of-pull of the VMO muscle tends to counter this
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affect. Any mechanical relationships or activation of these muscles can produce alteration of the
tracking that may increase pain (Grelsamer & McConnell, 1998 and Ng, 2002).

B. Current Treatment Options for PFPS

There are several ways currently employed in the treatment of PFPS. One rehabilitation
program incorporates taping techniques to improve patellar tracking.

In this technique,

Kinesiotape (an elastic tape) is applied over the patella to pull it in a medial direction. It is
thought that this temporarily relieves the PFP if the pain was caused by maltracking and the
associated increase lateral patellar pressure. This allows the patient to strengthen the medial
muscles, stretch lateral structures, and restore balance to the system (McConnell, 1986). When
muscle balance is restored, it is hoped that the tape is no longer necessary. The McConnell
patellar taping program is intended to correct patellar tracking by medializing the patella.
The McConnell taping method (Grelsamer and McConnell, 1998) and physical therapy
(rest, ice, or combination) are the often the first measures taken to reduce PFP. Another method
of treatment is muscle stimulation. In this technique, medial muscle groups are electrically
stimulated at a low frequency. The treatment is done daily for up to 8 weeks in hopes of
improving the force production characteristics of the VM muscle. This treatment method has
been reported to have some positive outcomes (Kannus, 1999).
A surgical method of treating PFPS is termed a lateral release. In this procedure, lateral
retinaculum of the patella is cut to reduce the lateral forces produced by this fibrous tissue (Fox,
1993). Following recovery, it is hoped that the patella will track in a more normal fashion thus
reducing PFP.
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All of the aforementioned treatment methods for PFPS have one thing in common; they
are all attempting to correct a mechanical imbalance in forces surrounding the patella that are
thought to contribute to the patient’s reports of pain. Reducing pain is ideal in any rehabilitation
program since it allows normal movement patterns to be restored (Fox, 1993 and Fredericson,
2006). Each method has had limited success, but no one method has shown long term
improvement with all patients. A new method of treatment is being proposed in this study to
rebalance the muscle surrounding the patella by temporarily decreasing the force production
capability of the lateral muscle group. It is hoped that this will decrease pain and increase the
exercise tolerance of the patient so that force production balance can be restored.
C. The Nature, History, and Usefulness of Botulinum Toxin Type A

Botulinum Toxin Type A, (BTX-A), is more commonly known as Botox (Botox,
Allergan, Irvine, CA). Botox is a poison which acts at nerve endings and inhibits the release
of acetylcholine, thus decreasing muscle force production. In controlled doses, the muscular
paralysis is reversible and can ameliorate symptoms in patients with muscle imbalances (Tortora,
1996 & Sastre-Garriga, 2001). When used for PFPS, chemodenervation can persist for three
months (Lim, 2006 and Singer, 2006). After this time, axonal branching is re-established with
the neurotransmitter junction.
In 2006, Allergan Inc. reported Botox had helped patients get relief from certain
medical conditions throughout 75 countries. Rajeev Nagi, a director of sales and marketing in
India for Allergan Inc., claimed Botox had approximately 20,000 users in 2007
(Botoxcosmetic.com). Botox has been approved by the U.S. Food and Drug Administration
(FDA) as a cosmetic treatment and to medically treat some dystonias (Sastre-Garriga, 2001). It
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is reported safe, but does have some potential side effects. Users may experience local allergic
reaction, hematomas, and burning at injection sites or anaphylactoid reaction caused by
injections and excessive weakness that can persist for 3 to 6 months.
One of the problems with traditional therapies to improve the muscle balance surrounding
the PFJ is that all of the quadriceps muscles have common neural innervations. As a result, it is
nearly impossible to strengthen one quadriceps muscle without strengthening all of them
(Barney, 1980). If isolated strengthening is required to restore overall balance in the system,
then Botox can be used to selectively inhibit the VL muscle group. Subsequent exercise will
strengthen the VMO muscle without activating the antagonistic VL muscle.

D. Supporting Studies

Research has previously reported using Botox injections to relieve PFPS. In 2006,
Singer et al deemed the use of Botox as a potential treatment for AKP in an 8 female open
labeled PFPS study. The purpose of this study was to reduce relative overall activity of the VL
muscle while retraining the antagonist VM muscle with 12 weeks of physical therapy. Subjects
reported reduced knee pain and increased participation in daily activities. Isometric quadriceps
muscle strength was maintained or improved at the 24-week follow-up. This was regarded as a
novel approach to improve patellofemoral mechanics to establish treatment efficacy.
Another opened labeled pilot study at Virginia Commonwealth University (VCU)
investigated the use of Botox in a male subject with bilateral PFPS. The results showed
improvement in power and torque generation at the knee. In addition, there was an increase in
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VMO muscle fatigue resistance. Following the Botox injection, pain diminished at week seven
and had not returned at a 67 week follow-up.

E. Rationale for Study

It’s theorized that PFPS, is in part caused by VMO:VL muscle imbalance. While healthy
knees are speculated to have a 1:1, VMO:VL EMG ratio, this ratio has been reported to be
approximately 0.54 in PFP patients (Ng, 2006). A value of less than 1 implies that the VMO is
producing less force that the VL. This altered ratio can negatively impact the biomechanics of
the patellofemoral joint and contribute to improper patellar tracking. It is hypothesized that
VMO muscle weakness results in an imbalance with the antagonist VL muscle, contributing to
maltracking (Fredericson, 2006). The VL is the largest component of the quadriceps groupin
subjects with PFPS (Faramond, 1998) and supplies the most power.

It pulls the patella

proximally then laterally during extension. If this force is not countered by the medial muscle
group, then mechanical tracking problems can result. The maltracking may produce pain during
knee extension.
Pain has a secondary effect of altering the activation timing of these muscles. In 2006,
Sanchis-Alfonso reported changes in VM and VL activation in subjects with PFP during
voluntary knee extension. The movements included both concentric and eccentric contractions.
PFP subjects were compared to non-painful controls.

The findings showed that during

contractions, subjects with PFP had delayed VM activation. This would further compound the
negative impact of muscle imbalance. The use of Botox may be able to address the valgus VL
Q-angle associated with PFPS by strengthening VMO muscles. Stronger VMO muscles may
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reduce patellar maltracking during extension and reduce knee pain. Figure 2 illustrates the Qangle geometry within the PFJ along with the force vectors and insertion points for VL and
VMO muscle groups. Subtle alterations in summative force development and action, due to the
inhibitory effect of BTX-A in vastus lateralis [VL] and improved activation of vastus medialis
[VM], may potentially contribute to reduction in joint symptoms (Singer, 2006).

Figure 2: Q-angle geometry. The figure represents the Q-angle within the PFJ. “Schematic
depiction of the force vectors acting across the PFJ to the tibial tubercle (TT) [A]. Arrows show
relative insertions into the quadriceps tendon, which are demonstrated in the frontal plane MRI
in a normal individual [B] (Singer, 2006).

Reprint permission requested: 04August2008.
Direction of pull is illustrated for the VL and VM muscle groups.

The largest problem in treating patients with mechanical PFPS is the inability to isolate
the VMO muscle and to selectively increase its force production capability. If improper lateral
patellar tracking is truly the cause of the PFP in these patients, then increasing the pull of the
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VMO muscle to balance the VL muscle force would seem vital in restoring normal patellar
movement. Past rehabilitation efforts have focused on identifying techniques to selectively
strengthen the VMO to improve the force balance on the patella. To date, the current treatment
options only provide temporarily relief and do not address the underlying biomechanical
deficiencies of the PFJ.

F. Statement of Purpose

The purpose of this research study is to further test the effectiveness of Botox in the
treatment of muscular imbalances related to PFPS. The study extends the impact of previous
findings by employing a closed-label double-blind protocol. This minimizes the effects of
examiner and subject bias on the results. Collected data will include kinematic, kinetic, and
surface electromyography (sEMG) to analyze mechanical, spatial and temporal relationships of
muscle that contribute to patellar movement. Additional self-report data will be collected from
subjects to assess their perceived change in pain resulting from treatment. All data collection and
utilized instrumentation were similar to unpublished pilot work.
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Chapter 2: Experimental Methods

A. Subject Enrollment
The study was designed using a double blind protocol approved by the VCU internal
review board (IRB). The IRB ensures human research conducted at the University is compliant
with federal, state, and local regulations. The protocol was written with an expectation that 20
subjects would be recruited over a year time frame from a sample of convenience. Previous
literature using preliminary data found Botox™ treatment as a novel approach to restoring knee
extensor muscle balance with those with PFPS. Therefore all subjects were pre-screened by a
licensed physician executing past literature criteria for PFPS. After pre-screening, the subjects
could enroll in the study if they met the following inclusion criteria:


18-40 years of age



anterior knee pain (AKP)



pain during at least two of the following activities: climbing stairs, hopping,
kneeling, prolonged sitting, running, and squatting



the subject must have insidious onset



patellar pain averaging at least 4 cm on a 10 cm visual analog scale



knee pain for at least one month



pain on patellar palpation

Subjects were excluded from the study if they had a history of knee surgery, dislocation, or
clinical evidence based on history and clinical exam (See Appendix C form A).
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Four female subjects met the inclusion criteria and were enrolled in the study.

One of

those subjects re-enrolled in the study after her other knee became symptomatic. She had
already successfully completing the protocol on her first knee. Both knees met the inclusion
criteria for this study and were treated serially. In total, 5 knees were treated. Subjects were
randomly selected to receive either Botox™ treatment or placebo control.

This random

assignment resulted in one subject receiving Botox™ treatment. One subject decided not to
continue after baseline testing and was removed from the study. The total number of knees
treated in this study was n=4.

B. Target Data
Two types of data were collected in these experiments; subjective and objective. The
subjective data included questionnaires designed to assess pain and functional levels. The
objective data included quantifiable measures of performance.
Subjective Data
Subjective data is defined as data supplied by the subject.

Questionnaires have

successfully been used in anterior knee pain research to collect these data. These include the
Anterior Knee Pain Scale (AKPS), Functional Index Questionnaire (FIQ), Lower Extremity
Functional Scale (LEFS), and Visual Analog Scale (VAS) (Crossley, 2004 & Harrsion, 1995).
The AKPS is a 13-item questionnaire with discrete categories related to various levels of
current knee function (Crossley, 2004). The subject is asked to rate their knee symptoms in
regards to weight bearing support, presence of a compensatory limp, muscle atrophy, and pain
when jumping, squatting, or running.
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The FIQ questionnaire is an eight-activity multiple-choice rating form. Example FIQ
questions include knee function when walking 32 blocks up to a mile. This toll is designed to
assess functional abilities.
The LEFS rates exercises with a ratio scale of extreme difficulty to with no difficulty. The
daily tasks that are rated include usual work, hobbies, bathing, walking, putting on shoes,
squatting, lifting objects from the floor, performing light activities, getting in/out of car, walking
2 block to a mile, ascending/descending 10 stairs, standing and sitting for 1 hour, running on
uneven ground, making sharp turns while running fast, hopping, and rolling out of bed.
The VAS can be used to quatify subjective data. In pain assessment, it is represented to
the subject as a horizontal line, 10 centimeters in length, anchored by a pain descriptor at each
end (see Appendix D). This descriptor is typically “no pain” at the left end, and “extreme pain”
at the right end. The subject is asked to mark their perceived pain on the line with a vertical
mark. The location of this vertical mark from the left end of the line is measured by the
examiner. This allows the data to be converted to an ordinal scale for analysis.
Objective Data
Objective data is defined as data from physical exam or laboratory collection. Functional
measurements such as, (1) jump height, (2) isokinetic force production, (3) isometric force
production, and (4) fatigue measures are commonly used in exercise research to quantify subject
performance.
1. Jump height
Force plates can be used to measure jump height. A force plate is an instrument designed
to measure ground reaction forces in three directions; vertical, anterior-posterior, and mediallateral. They are used in biophysics and human performance research. The plates are typically
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mounted in the floor. When a force is applied to the plate, deformation is relative to the
magnitude of the force applied. The deformation results in a proportional load cell voltage
change (Grimshaw, 2006). If a subject is asked to jump vertically from a force plate and land
back on the plate, their “hang-time” (or time in the air) is proportional to the height their center
of mass was elevated. This hang-time can be converted to vertical jump height using the
following constant acceleration equation:

Jump height in inches = 192 (t/2)2

All force plate data were sampled at 1000Hz with a 12-bit A/D converter and stored for off-line
processing.

2. Isokinetic force production
Isokinetic testing is a reliable tool for strength assessments (Tiffreau, 2007), even in weak
subjects. Isokinetic means constant velocity and requires a specialized piece of equipment called
an isokinetic dynamometer. There are several available commercially and they are frequently
used in rehabilitation and research settings. The isokinetic dynamometer is an electromechanical
device designed to quantify extremity force production by having the subject perform against a
constant velocity load through a defined range of motion. It is a dynamic test. A computer
monitors force, angular velocity, and position of a rotating lever arm as the subject pushed
against it. The maximum angular velocity is preset by the examiner. During isokinetic testing,
the subject is instructed to push as hard as they can on the lever arm. As the preset velocity is
reached, the dynamometer compensates by increasing the resistive load against the limb. This
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limits the maximum velocity the subject can achieve and effectively creates an isokinetic
environment.

Force is recorded as the dependent variable and a measure of performance.

Variable derivatives included average work, average power, and peak torque.

In these

experiments, the subject was set up to flex and extend their knee against the load.
The isokinetic testing protocol involved having the subject first perform a five-minute
warm-up on a stationary bike at a 50 watts load (Coburn, 2005). The dynamometer (Biodex
System 3, Biodex Medical Systems Inc, Shirley, NY) was setup for knee testing and adjusted to
fit the subject based on the Biodex testing manual instructions (Figure 4). The Biodex is
designed to control velocity and reliably measure power, angular velocity, and torque (Drouin,
2001). The subject was securely strapped in place in a seated position to minimize compensatory
movements. Subjects were then asked to perform single limb concentric knee extension exercise
at velocities of 180°/sec, 90°/sec, and 45°/sec through a range of 10°-90°. The range of motion
(ROM) was set using a universal goniometer and standard anatomical landmarks (axis = lateral
epicondyle, distal reference = lateral malleolus, proximal reference = greater trochanter). The
lateral epicondyle was aligned with the axis of the Biodex moment arm to minimize shear force
on the knee.
Figure 3: Biodex system
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The subject was allowed to practice the isokinetic activity until they felt comfortable with
the test. They were instructed to perform the knee extensions as quickly as possible and
performed three sets of five repetitions. A 60-second rest was provided between sets. All
isokinetic data were sampled at 1000Hz with a 12-bit A/D converter and stored for off-line
processing.

3. Isometric force production
Isometric force production has been used to assess muscle function in previous research
(Coburn, 2005). Isometric or static functional tests are used to evaluate muscular contractions at
a fixed limb position. Theoretically, isometric contractions occur when the muscle develops
tension with no changes in muscle length. In these experiments, force production was measured
at 30°, 60°, and 90° of knee flexion. The Biodex was held in a fixed position and the subject was
asked to forcefully extend their knee in a sustained contraction at each angle for five second.
The force from this maximum voluntary contraction (MVC) was recorded. Three sets were
performed at each angle with a 60-second rest between tests. All isometric data were sampled at
1000Hz with a 12-bit A/D converter and stored for off-line processing. The force data was
converted to torque for analysis.

4. Fatigue measures
Fatigue is a reversible physiological phenomenon that can be measured during isometric
muscle contractions (Ng, 2002). This is accomplished by recording the muscle’s electrical
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activity during the contraction. It can be done using surface electrodes with a technique called
surface electromyogram (sEMG). The amplitude of the electrical activity is directly related to
the muscle contraction force via the excitation-contraction coupling process. sEMG amplitude is
often processed through a root-mean-squared (RMS) algorithm and has been shown to have a
quasi-linear relationship with muscle force production (Kallenberg, 2008).
When submaximal isometric contractions are held until exhaustion, force production
decreased. Findings suggest that a drop in mechanical efficiency contributes to this decline
(Ebersole, 2008). Subsequent changes in the RMS signal can be observed (Wnek and Bowling,
2008). Changes in the power spectrum of the sEMG signal can be seen as well. The power
spectrum is quantified by transforming time-domain data into the frequency-domain by
employing a Fourier Transform. As a muscle fatigues, the median frequency has been shown to
decrease (REF).
sEMG data collection was accomplished using a 4-channel commercial system (Noraxon
Myosystem 1200, Scottsdale, AZ). This is a differential system with a CMRR of > 100dB and a
bandwidth of 10Hz to 500Hz. Skin preparation involved cleaning the skin surface with 70%
isopropyl alcohol and wiping it dry.

Electrode pairs were place parallel to muscle fiber

orientation for vastus medialis oblique (VMO) muscle and vastus lateralis (VL) muscle of the
study leg using standard anatomical landmarks for reference (Figure 5). The VMO electrodes
were placed superior and medial to the patellar apex a distance of “4-finger” widths. The VL
electrodes were placed superior and lateral to the patellar apex a distance of “one hand-breadth”.
The electrodes for each muscle group were approximately 2mm apart. A single ground electrode
was placed on the lateral epicondyle.

18
Figure 4: Approximate EMG Placements for Vastus Lateralis and Vastus Medialis muscle belly
and ground reference placements.

During the fatigue testing protocol, the subject was asked to sustain an isometric
extension contraction at 80% of their maximum for 40-seconds with their knee held in a fixed
position (60° flexion). Visual feedback provided a target to assist in this process. The 80%
threshold was calculated by averaging the maximum isometric force data from the isometric
force production trials performed at 60° of knee flexion. The fatigue test was repeated three
times with a 60-second rest between trials. Verbal encouragement was provided. All sEMG
data were sampled at 1000Hz with a 12-bit A/D converter. A digital 2nd order Butterworth filter
was used to band limit the data between 20 and 200 Hz and the data were stored for off-line
processing.
Fatigue was quantified by processing the sEMG data with a Fast Fourier Transform
(FFT). The 40,000 data points (40-seconds at 1000Hz) were temporally processed in sequential
windows of 1024 points with an overlap of 512 points. The median frequency (MnF) in each
window was computed and stored. A time-indexed plot of these frequencies was created and a
linear regression line was fit to the data. The slope of this line is an indication of relative fatigue
with a negative slope indicating a fatiguing process (Yassierli, 2006).
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C. Study Design
The study design included five treatment sessions. After the initial visit (session 0), data
were collected four additional times over a 12-week period. Each subject followed the same
outline and basic exercise regimen.
Session 0:
Documentation of subject medical history, physical exam (height, weight, blood pressure,
and temperature), and a knee exam were performed. Data forms for inclusion, exclusion criteria,
diagnosis, eligibility, subject name and contact information were collected.

Subjective

questionnaires on knee pain and function were given to the subject to document their knee pain
three days prior their testing session.
Session 1: (3-7 days following session 0)
Baseline lower extremity functional and pain scale data were collected. The subjects
were instructed to climb one flight of stairs and descend the same flight of stairs, rating their pain
using the VAS. The subjects were also instructed to perform three independent vertical jumps on
a force plate (Bertec model 4060). After completing the jump tests the subjects they rated their
current anterior knee pain using the VAS. Isometric, isokinetic, and sEMG data were also
collected.
Subjective data were collected by having the subject complete the AKPS, LEFS, and FIQ
forms. In subsequent testing sessions, subjects completed this questionnaire at home, one day
prior to arrival. The subjects were asked to record their data around the same time of day in an
effort to improve the consistency of this measure.
Following the baseline testing, the subject was seen by study physician to receive
injections of Botox™ or placebo. The pharmacy provided these materials in an unmarked syringe.
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All examiners and subjects were blinded to the content of the syringe. The Botox™ dose
contained 100 units of the drug. The placebo dose contained 1cc of saline, 1cc of 1% lidocane,
and 1 drop of bicarbonate. The study physician administered the injections at four VL sites
using ultrasound imaging to guide location. Finally, a physical therapist instructed the subject in
the home exercise program (HEP) to be followed for the next 12 weeks. The details of this
program can be found in the following section (D. Home Exercise Program).
Session 2-4: (Visits for 4, 6, and 12-week post injection)
Each of the next 3 sessions was the same. The subjects were asked to complete the pain
scaling forms three days prior to the session. They were also asked to complete the AKPS,
LEFS, and FIQ forms one day prior to the session. These forms were then returned to study
director on the day of testing. At that time, subjects were asked if any changes in general health
had occurred since last visit. Jump tests, stair-climb, isokinetic, isometric, and sEMG measures
were taken and recorded as before. At the completion of the study, each subject commented on
their overall improvement, consistency, or no change after treatment.
At the conclusion of each testing day the data were exported (Appendix B). Data
analysis was performed with custom programs written with Matlab software (version 7.0; The
Math works Inc., Natick, MA). Appendix C provides the calibration formulas to convert the
Biodex data (voltages) into real-world values. Knee torque is defined as the Biodex load cell
force x the length of the moment arm, where the moment arm length is the distance between joint
center and the lateral malleolus of the subject.
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D. Home Exercise Program

Subjects were provided with instructions for a home exercise program. These exercises
were carefully selected since PFPS can be aggravated when patellofemoral compression forces
are added to the joint. A description of each exercise their rationale follows.

The HEP included:


Single limb squats -- Squats isolate the VMO with medial adduction at the end of the
squat. Performing single leg exercises ensures equal efforts per limb.



Squats with hip adduction – The adduction exercises attempts to isolate the VMO.



Side lying abduction -- The abductions exercise attempts to isolate the VL.



Straight leg raises -- The straight leg raises strengthens the entire quadriceps complex as a
whole maximizing quadriceps strength.



Side raise hip adduction -- The adduction exercises attempts to isolate the VMO.



Iliotibial (IT) band stretches -- IT band fibers blend and mix with the fibers of the lateral
retinaculum, thus if they are tight, they can contribute to lateral patella tilting and
excessive pressure on the patella. The IT stretches can allow the soft tissue of the patella
tendon to loosen around the patella structure. It can also allow less lateral pull on the
patella to occur with the knee, therefore, correcting or alleviating irregularities in patella
alignment and possibly allowing relief. When a subject can increase the number of
repetitions over load, the muscular endurance should increase while increasing VMO
activity.
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Figure 5: Exercise examples prescribed for subjects to complete daily.
Single leg squats

Squats with adduction

ITB stretches

Side lying adductions

Side lying abductions

Straight leg raises

The initial number of exercise repetitions and sets were titrated by a physical therapist
according to each subject’s reported pain. Each subject was asked to increase their exercises in
repetitions or sets as they were able. Each subject kept a diary throughout the study to record
and to track their progress. This diary was provided to the examiner at the conclusion of the
study.
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Chapter 3: Results

This study included the analysis of subjective and objective data. The subjective data
included four subject questionnaires pertaining to pain and function. The objective data included
kinetic, kinematic, EMG, and functional measures.
Over the course of two years, four subjects met the inclusion criteria and were enrolled in
the study. Three completed the protocol successfully. One of those subjects re-enrolled in the
study for treatment of her other knee one year after her initial testing. T his subject received the
Botox treatment in one knee and the placebo in the other. Data from this subject is unique and
allows a comparison of subjective results. Analysis of these data points will be labeled as a
“Case Study”. The total knees tested in this study was n=4. One additional subject is included
in some of the presented results. These data are from a previous pilot study with a similar
protocol in which the subject had both knees treated with Botox.
Research bias was minimized by using a double blind protocol where subjects and
researchers were blinded to the treatment type (Botox™ or placebo) during both the data
collection and processing. Syringes were prepared by the MCV pharmacy and delivered to the
physician unmarked. At the conclusion of the study, one subject had received the Botox
treatment and three had received the placebo treatment. Throughout the remainder of this paper,
subjects are labeled based on their injection type: Botox™, Placebo 1, Placebo 2, and Placebo 3.
The case study data compares Botox™ to Placebo 2.
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A. Subjective Results

Subjective data is defined as data supplied by the subject.

The uses of subjective

measures are well documented in the literature (Crossley, 2004). These were used to assess and
quantify pain and functional changes throughout this study.

1. Anterior Knee Pain Scoring (AKPS)
The AKPS is a 13-item questionnaire with discrete categories related to various levels of
current knee function (Crossley, 2004). The subject is asked to rate their knee symptoms in
regards to weight bearing support, presence of a compensatory limp, muscle atrophy, and pain
when jumping, squatting, or running. These questions are weighted and the subjects’ responses
are summed to provide an overall index. A score of zero implies severe disability; while one
hundred represents no pain and normal function (Kujala, 1993). Figure 6 displays the subjects’
AKPS results and compares subjects’ progress internally and externally over the course of this
study.
Figure 6: Anterior knee pain scoring for Botox treatment and placebo injections. This figure is
a graphical representation of the data presented in Appendix A.
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A positive change score represents an improvement in function and a decrease in reported pain.
All subjects had a positive change score when comparing Session 1 to Session 4. The positive
change score signifies sustainable improvement.

2. Functional Index Questionnaire (FIQ)
The FIQ questionnaire is an eight-activity multiple-choice rating form.

The FIQ

questions were weighted from zero to two based on the subjects’ self-reported ability to complete
specific tasks. The task scores were summed to create a composite score for each testing week.
The highest achievable score was sixteen and the lowest was zero. A score of zero indicates the
inability to perform all activities and sixteen indicates no issue performing any of the activities.
Results are shown in figure 7.

Figure 7: Functional index scoring results for the Botox treatment and placebo subjects. This
figure is a graphical representation of the data presented in Appendix A. A higher FIQ implies
higher function capabilities.
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All subjects reported an improvement in performing functional tasks when comparing
Session 1 to Session 4.

3. Lower Extremity Functional Scaling (LEFS)
The LEFS is a 19-item questionnaire related to normal daily activities. The ability to
perform these activities is objectively defined using the following criteria (Brinkley, 1999):


0 = the subject was unable to perform activity



1 = the subject had quite a bit of difficulty performing the activity



2 = the subject had moderate difficulty performing the activity



3 = the subject had a little bit of difficulty performing the activity



4 = the subject had no difficulty performing the activity

The sum of the scores was divided by the maximum possible points to create a percent composite
score. The maximum obtainable score for LEFS is 76 points. A subject who experiences no
difficulty with all 19 tasks would score a 100% as their LEFS result. Results are plotted in figure

8.
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Figure 8A: Illustrates the LEFS results for the Botox treatment and placebo subjects. The
Botox subject had a change score of +22%. The Placebo subjects had an average change score
of +8%. This figure is a graphical representation of the data presented in Appendix A.

LEFS Results
Scoring (%)

100
80

Session 1 (week 0)

60

Session 2 (week 4)

40

Session 3 (week 6)

20

Session 4 (week 12)

0
Botox™

Placebo 1 Placebo 2 Placebo 3
Treatment

The subject treated with Botox had the highest overall score experiencing only mild
difficulty performing squats, running on uneven turf, and making sharp turns while sprinting. All
subjects were able to perform daily tasks, such as rolling in bed and getting in and out of the bath
and vehicle. However, the placebo subjects reported extreme or mild difficulty with recreational
activities, such as walking two blocks to a mile, squating, running on uneven turf, and making
sharp turns while sprinting.

When comparing the Case Study results, the limb treated with Botox initally had a total
score of 69%, but following treatment, progressed to 91% by week 12. The subject experienced
little difficulty with 3 out of the 19 tasks. However, when the same subject later received the
placebo treatment on the other leg (Placebo 2), the subject initally scored 80% and received a 12
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week score of 81%, noting performance difficulty in 8 out of the 19 tasks. A comparision
between the placebo control injective limb resuted in a higher rating of five points versus the
Botox treated limb. These tasks included recreational activities, squatting, walking 2 blocks to
a mile, sitting and standing for an hour, running on unven turf, and making sharp turns while
sprinting.
Figure 8B: Illustrates the LEFS results for the Case Study subject. The Botox subject had a
change score of +22%. The Placebo2 had an average change score of +1%. This figure is a
graphical representation of the data presented in Appendix A.
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4. Visual Analog Scaling (VAS)
VAS is a measurement tool to assess knee pain characteristics that cannot be directly
measured using other instruments (Gould, 2001). The amount of pain a subject feels ranges
across a continuum from “no pain” to “extreme pain”. The assessment is highly subjective and
most valued when looking at change within subjects. These data are of less value for comparing
across subjects (Gould, 2001). Figure 9 illustrates the VAS results for ascending and descending
stairs and jumping for the subject treated with Botox, averaged placebo, and case study data.
Figure 9: VAS Results for subject treated with Botox™.
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The Botox subject perceived pain scoring diminished throughout the study for
ascending and descending stairs and while jumping. Initially, pain was reported to be in the
moderate to severe range. At the conclusion of the study, the subject reported no pain. The
placebo controls continued to report mild pain at the end of the study.
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C. Objective Results

Objective data is defined as data from physical exam or laboratory collection. Functional
measurements were used to quantify subject performance. Testing was accomplished using an
isokinetic dynamometer (Biodex), a surface EMG system (Myosystem 1200, Noraxon), and a
force plate (Bertec). Data were again collected four times during the course of the study at weeks
1, 4, 6, and 12. Results are reported below.

1. Isokinetic Results
Concentric isokinetic leg extension data were collected using a Biodex isokinetic
dynamometer (Biodex Inc, NY). Subjects were then asked to perform single limb concentric
knee extension exercise at velocities of 180°/sec, 90°/sec, and 45°/sec through a range of 10°-90°
of knee flexion. Intra subject data were averaged for each velocity. No verbal encouragement
was provided during data collection to allow each subject to define their personal maximum
effort. Work and power were calculated for each trial. The results are summarized in Appendix

a.

Work

Work is defined by Newton’s Second Law of angular motion. The law states that
a net torque produces angular acceleration of a body that is directly proportional to the
magnitude of the torque, in the same direction as the torque, and inversely proportional to
the body’s moment of inertia. This law is often stated as, "torque equals moment of
inertia times angular acceleration (T = I)". Like its linear analog, the expression of for
angular work is a function of force and distance moved:
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W
=
Txθ
Where:
T is torque in N-m and θ is the angular displacement in radians.
Work is measured in joules (J), which is defined as Nm or kgm2/s2.
When using the Biodex during knee extension activities, torque is produced by
the subject when they apply a force to the rotating arm at some distance from the axis of
rotation. Work is done when this torque produces angular movement of the arm. This can
also be expressed as rotational kinetic energy (RKE = ½ I2; where I = the moment of
inertia, and  = the angular velocity in radians/sec). Figures 10A-D illustrate the angular
work done in order of 180°/sec, 90°/sec, and 45°/sec using the work energy theorem.
Average work, power, and standard deviations are presented in Appendix A9.

Figure 10A: Work results at 180°/s.
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Figure 10B: Work results at 90°/s.
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Figure 10C: Work results at 45°/s
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Figure 10D: Work results at 45°/s for Case Study
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In general, angular work was greater at the lower angular velocities for all subjects. The
Botox™ subject had a significant decline in angular work following the injection.

b. Power
Power is the product of torque and angular velocity. Power is defined as the amount of
work performed per unit time (Cutnell and Johnson, 1997) and expressed at Nm/s (or Joules/s or
Watts).
P

=

Tx
T is torque in N-m and  is the angular velocity in radians/sec.

Where:

Figures 11A - D illustrate power results from kinetic angular motion testing at 180°/s,
90°/s, and 45°/s.

Figure 11A: Power results at 180°/s
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Figure 11B: Power results at 90°/s
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Figure 11C: Power results at 45°/s
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Figure 11D: Power results at 45°/s for Case Study
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The power results illustrate more variability at the higher velocity with higher power
generation at these velocities. The Botox™ treated subject was less powerful at week 4, but
recovered by week 6.

2. Isometric Results
Using the Biodex to perform isometric contractions, torque was measured at prescribed
angles. Torque is defined as:
Torque (τ)
Where:

=

Fι

(Cutnell and Johnson, 1997)

F is the magnitude of force and ι is the lever arm

Torque is measure in Newton * meter (Nm)
Isometric extension torque production was measured and recorded for orthopedic knee
angles at 30°, 60°, and 90° of flexion. The isometric data for each subject was averaged for all
trial sets. Results are plotted in figures 12A-C and the subjects averages are reported in appendix
C.
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Figure 12A: Botox™ subject torque results at 30. This figure is a graphical representation of the
data presented in table 4.
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Figure 12B: Placebo torque results at all three isometric testing angles
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Figure 12C: Case Study torque results at 60°
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There is a similar pattern at all three isometric contraction angle. However, the ability to
produce knee extension torque is maximized at a knee angle of 45° due to muscle length
physiology and anatomical mechanical advantage, so it is expected that the torque levels at 30°
and 60° would be greater than at 90°. Each subject increased their torque production over time
with the highest amount of torque produced during the final week of testing.
Both the Botox™ and placebo limbs increased torque production at week 4, with the
exception of placebo 3 in the 30° trail. The Botox™ treated limb produced the highest torque at
60°, but the placebo control 2 produced the highest overall torque.

3. EMG
Electrodes were placed on each subject to measure VL and VMO muscle electrical
activity during a sustained isometric contraction. The data was processed with a root-meansquare (RMS) algorithm to allow averaged magnitude data to be used to compute an activation
ratio (VMO:VL). The RMS process involved full wave rectification of the EMG data, followed
by digital integration using a 25ms time constant. Typical results are illustrated in figure 14A.
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Figure 13A: The three plots in figure 13A illustrate typical sEMG responses during the isometric
testing. Note that torque production was constaint during the contraction. Also note that the raw
EMG data is presented in blue and the RMS data is presented in red.

In figure 14A, the top figure illustrates the production of knee torque initiated around 3
seconds and ending after 9 seconds. The middle plot illustrates typical sEMG results for the VL
muscle. The bottom plot illustrates a typical sEMG response for the VMO muscle. From these
data, EMG ratios were computed from the middle 3 seconds of contraction data. This was done
by dividing the average RMS VMO value by the average RMS VL value. Isometric contractions
were tested at 30°, 60°, and 90° of knee flexion. In figures 14A and B, VMO:VL EMG signal
ratios are illustrated at 60°. These ratios were used to report relative muscle activity for all trials.
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Figure 14A: VMO:VL EMG signal result ratio for Botox™ and the placebo controls averaged
data at the 60 ° position.

EMG ratios
VMO/VL ratios

2.50
2.00
Botox

1.50

Placebos

1.00
0.50
0.00
0

2

4

6

8

10

12

Testing point (weeks)

SEM was 0.043 for VMO/VL for placebo control ratios. Small values signify that the
means for each placebo differ by 0.043. This implies a consistency within the placebo data.

These data suggest that the VMO was more active that the VL muscle at week 6 in the
Botox™ treated subject. This ratio returned to baseline by week 12. The average placebo data
showed no change over the course of the treatment. Figure 14B illustrates a similar trend in the
Case Study comparison.
Figure 14B: VMO:VL EMG ratio results for Case Study comparison.
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4. Fatigue
Muscle fatigue can be quantified by measuring a shift in sEMG median frequencies
(MnF) during a sustained isometric contraction. This shift to lower frequencies can be quantified
as an index of fatigue. Figure 15A is a typical response plot during VL fatigue analysis.

Figure 15A: Typical sEMG data from the VMO muscle during a sustained (40s)
isometric contraction.

The top plot illustrates raw sEMG data. The rectangular window (at the 5 second data
collection time) denotes the data used in the FFT analysis shown in the bottom plot. The FFT
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data was used to compute the MnF which is represented as a vertical red line. The FFT
calculation was sequentially executed though the temporal sEMG data stream, providing a series
of MnF values. These values were plotted and a liner regression line was fit to the points. An
example of this process is illustrated in Figure 15B.

Figure 15B: Typical sEMG median frequency shift for 3 trials of subject Placebo 3.
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time index

The average slope was recorded as an “index of fatigue” with a more negative number
indicating an increase in fatigue rate. This index is plotted for each session (data collection
point) and can be seen in figures 15C and 15D. Note that the Botox™ data includes pilot study
results.
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Figure 15C: VL Fatigue Differences from baseline. Botox™ data includes pilot study results.

Figure 15D: VMO Fatigue Differences from baseline. Botox™ data includes pilot study results.

The subject who received Botox™ treatment did experience more VL fatigue than
subjects who received the placebo. The VMO appeared relatively unchanged in the Botox™
subject, with fatigability increasing in the placebo subjects.
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5. Functional Testing
a. Force plate results
Force plates were used to estimate vertical jump height performance.

Figure 16A

illustrates a force plate similar to the one used in this study. The formula used to determine jump
height was based on the amount of time each subject was suspended in the air. The equation
used for the jump tests results was:

Jump height (in inches) = 192 (t/2)2
Where: 192 = a constant based on constant acceleration equations
t = time in seconds that the subject is airborne

Longer suspension times represent higher jump height. Averaged flight time during each testing
period with their standard deviation is reported in the appendix.
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Figure 16: A. An illustration of a typical force plate jump test exercise. B. Illustration of a jump
test plot using motion monitor for research after a jump test on a force plate. C. Subject results
for force plate jump test trials.

A.

B.

In figure 16A, when the subject leaves the force plate, as seen at 3 seconds, there is a loss
of foot to force plate contact (the subject becomes airborne). The subject returns to the force
plate at the 3.4 second time point. In this example, with the subject airborne for 0.4s equates to a
jump height of 7.68 inches. Figure 16C illustrates average jump data from 3 trials at each
session. Raw data, averages, and their standard deviations are reported in appendix C.
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Figure 16C: Jump height changes.

The Botox™ subject improved in jump height over the course of the study. When
comparing baseline to final testing point, the subject who received Botox™ improved in total
jump height by +1.91 inches, placebo 1 by +2.73 inches, and placebo 3 by +0.63 inches of a
difference in vertical jump height. Placebo 2 had a total jump height difference of -0.19 inches
in jump height. Recall that the Botox™ subject and placebo 2 was the same person. The case
study data shows that the Botox™ treatment resulted in a jump height 2.10 inches higher than the
placebo treatment.

b. Weekly Exercises
Weekly exercises were directed by a physical therapist. The subjects were to follow
physical therapists instructions off site.

Any issues completing exercises were to be

communicated with the physical therapist.
Figures 17A-F illustrate weekly exercise compliance (in repetitions) and pain scores.
Repetitions and perceived pain were averaged for a weekly total score. Pain scores were based
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on 0, being no pain, and 10, being the most excruciating pain. Subjects were asked to increase
the number of exercise repetitions as tolerated.

Figure 17A: Weekly exercise result plots for single leg squats illustrating repetition and
perceived pain.
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All subjects were able to maintain the prescribed, (3 repetitions as suggested by the
physical therapist), repetitions for single limb squats. Performing single limb squat enables each
limb to work at their full potential without assistance from the other limb throughout the
exercise. The subject receiving Botox™ treatment was able to increase from two to seven
repetitions.

This was a unique pattern only seen with the Botox™ treatment.

Pain also
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decreased five points over the course of the study. The placebo subjects showed a fluctuating
pattern of perceived pain for this set of exercises.

Figure 17B: Weekly exercise graphs for squats with adduction based on repetition and perceived
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In figure 17B, all subjects were able to maintain the prescribed repetitions for squats
with adduction. The exercise requires the subject to maintain a 90 ° angle at the knee joint with a
slight push inwards while performing squats. Three out of the four subjects were able to
increase their repetitions. The subject receiving Botox™ treatment in one limb and placebo
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control in the contralateral limb (placebo 2) both decreased pain by five points. A three point
decrease was achieved with placebo 1. Placebo 3 had fluctuations in pain rating throughout the
course of the study with a one point difference in pain.

Figure 17C: Weekly exercise graphs for IT band stretches based on repetition and perceived
pain.

Botox™ (pain rating decreased 1 to 0)

Placebo 1 (pain rating decreased 6 to 0)

Placebo 2 (pain rating unchanged)

Placebo 3 (pain rating not reported)

In figure 17C, the ten prescribed IT band stretch repetitions were maintained throughout
the study. The Botox™ treatment subject and placebo 1 had decreases in their ITB pain. Placebo
2 remained at a three out of ten pain scale, while placebo 3 did not report any pain levels.
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Figure 17D: Weekly exercise graphs for side lying abductions based on repetition and perceived
pain.

Botox™ (pain rating decreased 5 to 1)

Placebo 1 (pain rating decreased 4 to 1)

Placebo 2 (pain rating decreased 5 to 2)

Placebo 3 (pain rating decreased 2 to 1 with fluctuations)

As represented in figure 17D at week 4, the Botox™ treated subject had increased the
quantity of repetitions for side lying abduction. All placebo control subjects maintained the
original prescribed two repetitions throughout the study. The subject treated with Botox™ also
had a 4 point reduction in pain. The placebo controls had a two point average reduction in pain
rating for side lying abductions.
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Figure 17E: Weekly exercise graphs for straight leg raise based on repetition and perceived pain.

Botox™ (pain rating decreased 7 to 2)

Placebo 1 (pain rating decreased 6 to 3)

Placebo 2 (pain rating decreased 6 to 2)

Placebo 3 (pain rating decreased 5 to 1)

In figure 17E, the subject who received the Botox™ treatment increased their straight leg
raise repetitions by one at week 4. The other subjects maintained the prescribed two repetitions
throughout the study. The subject treated with Botox™ also had a five point reduction in pain.
The placebo controls each had a four point reduction in pain.
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Figure 17F: Weekly exercise graphs for side lying leg adduction based on repetitions and
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In figure 17F, the subject who received the Botox™ treatment increased the side raise
adduction by one repetition at week 4. The other subjects maintained their original prescribed
three repetitions throughout the study. Both the Botox™ treated subject and placebo 1 had an
overall three point reduction in their pain, while placebos 2 and 3 had a four-point reduction in
their pain.
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6. Summary of Results
Tables 1 summarize the intra and inter subjective data for the tests that displayed
noticeable changes in outcome responses.

Table 1: Summary of Treatment outcomes following Vastus Lateralis Injections
Botox™
Baseline Pain stair ascending
VAS versus post-injection
VAS (-10)
Baseline Pain stair
descending
VAS versus post-injection
VAS (-10)
Baseline Pain jumping
VAS versus post-injection
VAS (-10)
Lower Functional
Scale Change
Anterior Knee Pain
Scale baseline - 12 weeks
Functional
Improvement
Injection

Placebo 1

Placebo 2

Placebo 3

6-0 (no pain)

2-1

6-2

5-0

4-0

2-0

5-3

1-0

5-0 (no pain)

2-2

7-3

7-1

+ 23

+8

+1

+ 16

75 - 95

57 - 72

73 - 81

69 - 91

Greatly
improved
Botox

No change

Somewhat
better
Placebo

Somewhat
better
Placebo

Placebo

For the VAS, the treated subject experienced the greatest range of pain loss when
ascending and descending stairs. Placebo controls 1 and 3 also reported a final pain level of 0
cm on the VAS for descending stairs, but reported lower baseline ratings. The scale of change
was identical to that of the Botox™ treated subject.
The highest possible rating was an 80 for the lower extremity functional scaling (LEFS).
The higher valued change indicated the subject was closer to achieving a perfect score. The
Botox™ treated subject resulted in the highest value of LEFS change and also experienced the
greatest increase in lower functional tasks such as sitting, their typical work and activities.
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Placebo control 3 also reported a large improvement in knee function with placebo 2 and placebo
1 (see appendix C for questionnaires) rating the lowest functional improvement.
The highest possible score that could be obtained in the AKP scale was 100. The higher
score would indicate no functional knee deficiencies or pain. A 20% improvement in AKP
occurred with the subject who received the Botox treatment. Placebo 1-3 improved by 15%,
8%, and 22% respectively.
When including the Botox pilot data, the three limbs injected were similar in that they
were the only individuals to report a “greatly improved” overall study global rating.
Table 2 highlights the objective results.
Table 2: Report of the overall functional-testing summary

Subject ID
Botox
Placebo 1
Placebo 2
Placebo 3
Pilot 1

Isokinetic
Work
Power
↓
↑
no change
↑
↑
↑
↑
↑
NA
↑

Isometric
Torque VMO/VL
↑
↓
↑
↑
↑
↓
↑
↑
↑
NA

VL
↑
↓
↑
↑
↑

Fatigue
VMO
↑
↓
↓
↓
↑

The subject treated with Botox was the only report of decreasing overall work
performance. All subjects increased in power and torque. Isometric results indicated both limbs
in the case study decreased VMO/VL ratios. The other placebo controls increased in VMO/VL
ratio.

All subjects, with the exception of placebo 1, increased VL fatigue during testing.

Whereas, the VMO an increase in fatigue was demonstrated in the placebo control group and
fatigue resistance for the current Botox study subject and pilot subjects.
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Chapter 4: Discussion

The purpose of this research study is to test the effectiveness of Botox in the treatment
of muscular imbalances related to PFPS. Without a single standard of measure to categorize
subjects suffering from PFPS, this study utilized both subjective and objective tests. Subjective
data were collected in the form of questionnaires. These were established tools with proven
validity and are often valuable in assessing life-quality issues. Objective data were collected
from physical exam and laboratory experimentation. Double blind experimental methods were
used to minimize bias in all collected data.

Subjective data
A 10-pt change in Ankle Knee Pain Score (AKPS) reflects a functional change (Crossley,
2004).

All subjects had a positive change score in the AKPS.

This represents overall

improvement (or a decrease in pain) during the course of the study. The largest change was
reported by the subject who received the Botox™ injections (+20 pts). The subjects who
received Placebo injections also reported positive change, but of much smaller quantity. In fact,
the subject label Placebo 2 reported only a one point positive change from baseline. Recall that
this is the case study subject who received Placebo in one knee and Botox™ in the other knee.
Their subjective ratings can therefore be compared and illustrate the magnitude of difference
between the two treatments, with the Botox™ treatment producing more positive results.
The Functional Index Questionnaire (FIQ) is an eight-activity multiple-choice rating form
where subjects’ self-report their ability to complete specific tasks. A score of 16 indicates no
difficulty in performing all 8 activities. All subjects demonstrated improvement when measured

56
using this metric. The subject labeled Placebo 1 had the largest change score and reported
perfect score at their final data collection point. This conflicted with that subject’s global rating
of “slightly better” at the completion of the study. The FIQ data did not illustrate a difference
between the Botox™ and Placebo treatments. It has been reported to have poor reliability in
some applications (Crossley, 2004). This may be one of them.
The Lower Extremity Functional Scale (LEFS) is a 19-item questionnaire related to
activity. These activities range from normal daily activities to recreational exercises. This range
is thought to provide a good measure of overall knee function through the assessment of
perceived pain. Task scores are converted to a percent composite score.

A subject who

experiences no difficulty with all 19 tasks would score a 100%. The subject who received the
Botox injection started the study with a score of 69% and ended with a score of 91%. These
was a positive 22.5% overall change in performance. The subjects receiving Placebo injections
1, 2, and 3 showed improvements of only 7.5%, 1%, and 16% respectively with an average
percent composite score of 73 ± 2% by the end of the study. The case study findings were again
very telling, revealing a twenty point overall knee functional improvement for the knee treated
with Botox™ as compared to the Placebo as a control.
The Visual Analog Scale (VAS) is a measurement tool to assess knee pain characteristics
that cannot be directly measured using other instruments (Gould, 2001). The amount of pain a
subject feels is marked on a 10cm line. The left end of that line is labeled “no pain” and the right
end is labeled “extreme pain”. Subjects were asked to ascend stairs, descend stairs, and jump,
marking their VAS scores on a separate scale for each activity. Following patient recording, the
distance of the mark from the left edge of the scale was measured and recorded by the examiner.
Crossley (2004) reported that a change of two centimeters or more considered significant. All
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subjects showed a decrease in pain for each activity through the course of the study. The subjects
receiving the Placebo injection had an average decrease of approximately 3cm ascending stairs,
2cm descending stairs, and 3cm jumping. The subject who received the Botox injection had a
larger change. A 6cm decrease ascending stairs, 4cm descending stairs, and 5cm jumping.
Although all subjects demonstrated an overall reduction in pain during all three tasks, the subject
receiving the Botox treatment had the largest reported reduction (almost double for each
activity).
All of these tests reported varying pain reduction and improved knee function for all
subjects. Three of these tests differentiated the Botox and Placebo subjects. The test that did
not differentiate (FIQ) has been previously been reported as unreliable in some applications. The
overall improvement of the subjects could be a reflection of increased lower extremity strength
resulting from the imposed exercise program; however, the subject who received the Botox
treatment is the only one who reported both diminished knee pain and a significant overall
improvement in knee function. The Ankle Knee Pain Score (AKPS), the Lower Extremity
Functional Scale (LEFS), the Visual Analog Scale (VAS) appear to be the most responsive
outcome measures for the PFPS population.

Objective data
Isokinetic
One of the objective measures of performance used in this study was isokinetic force
production. Isokinetic means constant velocity. In this environment a subject is asked to actively
extend their knee against a device (Biodex) that limits terminal (angular) velocity. As the subject
pushes harder, resistance is increased using a closed-loop control algorithm.

Force
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measurements are converted to torque since that force is applied through a known moment arm
length. These torque measures are then converted into work and power for comparison across
subjects and trials. A comparison across different angular velocities provides a spectrum of
performance characteristics.
Isokinetic work was larger at lower angular velocities for all subjects. This is consistent
with the physiology of concentric (or shortening) muscle contractions and known force-velocity
relationships. At higher velocities, the muscle becomes less capable of producing force since it
cannot shorten fast enough. The subject who received the Botox™ injection had a decline in
work at week 4.

This is consistent with the anticipated inhibitory affect of Botox™ on

acetylcholine receptors at the muscle fiber motor endplates. This, in fact, was the purpose of the
study; to temporarily decrease the force production capability of the lateral muscle group (VL)
and allow the medial group (VM) to become relatively stronger. As the effects of the Botox
wore off (by week 12), muscle force production returned to appropriate levels. I sokinetic work
results did not reveal any significant difference between the study groups.
The rate of work produced by most muscle is rarely constant. Power is often calculated
to compensate for rapid time-course changes in work and may be more sensitive to performance
differences. Power is the product of angular torque and angular velocity. For all subjects, more
power was produced at higher velocities, but the variability of this measure was also higher.
This may have been due to subject instruction, limited verbal motivation during the performance
of this task, and/or limited practice time prior to the task. Some subjects find it difficult to use an
isokinetic dynamometer (Biodex) at higher angular velocities and may need more practice time
to become efficient users of this device. At lower angular velocities, data variability was much
smaller. The subject treated with Botox™ again showed a marked reduction in power at week 4,
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but showed signs of recovery by week 6. Isokinetic power results did not reveal any significant
difference between the study groups. All subjects had an increase in power production at all
angular velocities when comparing the end of the study to baseline. Since power is a more
robust measure of performance, this implies an improvement in performance in all subjects. It is
important to note that this increase does not signify a change in medial and lateral muscle
balance, it just represents an increase in total performance (and that includes force production).

Isometric
Another objective measure often employed to assess muscle performance is isometric
force production testing.

Isometric means constant length so these data represent force

production against a fixed load at a fixed position. Knee positions were varied to get information
at different muscle lengths. The data showed higher extension torque production at 30° and 60°
of knee flexion when compared to a knee position of 90° of flexion. This was expected since
muscle length-tension and patellar moment arm are maximized for performance at 45° of knee
flexion. All subjects increased their torque production over time with the highest amount of
torque produced during the final week of testing. The Botox™ subject was able to produce more
isometric torque than the Placebo subjects at all data collection points. The Botox™ subject also
had a slight increase in torque production at week 4. This is contrary to the expected affect of
Botox™ and may have been due to a learning effect. In fact, all subjects demonstrated this slight
increase at week 4. However, the case study comparison showed a difference between the
Botox™ and Placebo treatments that disappeared by week 12.
The Botox™ isokinetic and isometric results are consistent with a previous pilot study
(Pidcoe, 2006). The only difference is the magnitude of the measurements. The pilot study was
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performed on a single male subject who received Botox™ injects to the vastus lateralis muscles
of both knees. The current study ended up enrolling only women. There was no effort to
normalize data in these studies based on maximum voluntary force production, so the difference
in force magnitude is probably due to gender. The important point is the constituency of the
results. This provides validity to these results.

Muscle balance (sEMG)
Isometric and isokinetic testing are global measures of muscle performance.

They

measure force production (or the result of muscle activation) at the distal end of the segment
controlled by that muscle group. In our case, the quadriceps muscles are activated to produce
and knee extension force (or torque). Muscles produce force as a result of an excitatory neural
input.

This is an electrical event that results in an excitation-contraction coupling and a

subsequent shortening of the muscle fibers. The force produced is positively correlated to the
electrical activity in the muscle and can be measured using surface electrodes.

Applying

electrodes over the medial and lateral muscle groups allows an independent assessment of
performance. The collected data is described as surface electromyographic or sEMG.
Medial (VMO) and lateral (VL) muscle sEMG data was collect from each subject while
they performed isometric knee extension contractions. The ratio of VMO:VL activation was
computed and plotted. A value of 1 would represent a balance between these muscles and equal
electrical activity (or equivalent force production). Since the captured electrical activity is a
function of electrode placement, care was taken to standardize the methods based on previous
published studies. The consistent of the Placebo data suggests that the electrode placement was
not an issue.
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The VMO:VL ratios demonstrated an increase in VMO activation relative to VL in the
subject treated with Botox™. This difference was not evident by week 12 (the end of the study).
The Placebo group showed no change in VMO:VL ratio.
These results suggest that the Botox™ injection into VL was successful and decreased
the electrical activity of that muscle. Since electrical activity is correlated with force production,
it is safe to say that force production of the VL also decreased.

This would result in a

mechanical change in patellar tracking since both of these muscles attach to the patella and pull it
in opposing directions. Coupling these results with the subjective reports of decreased pain and
improved function suggests a positive outcome for the Botox™ treatment. These results are
consistent with current physical therapy practice where efforts are made to modify patellar
tracking to a more medial path in patients suffering from PFPS.

Muscle Fatigue
Another use of sEMG is to assess muscle fatigue. Neuromuscular fatigue is defined as
the inability of a muscle to produce force. Muscles differ in fatigue rate secondary to intrinsic
and extrinsic properties. These can include muscle fiber type, the general health of the subject,
nutrition, previous activity level, and genetics. It is expected that increased workloads will
increase fatigue. A work load can increase by increasing the external load or by decreasing the
muscle fibers responsible for carrying that load.

When the VL muscle was injected with

Botox™, it was expected that less fibers would be able to respond to neural excitation. This was
evidenced by comparing VMO:VL ratios and the general decrease in torque, work, and power
production. It was also expected that this would result in a higher fatigue rate in the VL, since
fewer fibers would be doing the same amount of work. The fatigue analysis supports this
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expectation. The VL muscle had a higher fatigue rate in the Botox™ subject when compared to
the Placebo subjects, while the VMO muscle results appeared unchanged.
Muscles do not add fibers to become stronger. In response to exercise, they do increase
the efficiency of each fiber therefore fiber diameter is frequently increased. This increase in
muscle “tone” or density may have a mechanical impact on patellar tracking, although the exact
ramifications are unknown. It is possible that the reported decrease in pain by the Botox™
subject was due, in part, to a change in patellar tracking resulting from re-balancing the
VMO/VL relationship. It is also possible that the decrease in pain reported by all subjects was
due, in part, to the overall effect of exercise on increasing muscle “tone”.

Functional Testing
Force plate
Subjective VAS data was collected from subjects following a jumping task. These data
showed all subjects reported a decrease in perceived pain by the end of the study. Objective data
quantifying the jump were also collected. Although there was a variation in the performance of
the Placebo group, the important comparison is the case study results. These showed that the
Botox™ treatment resulted in a jump height 2.10 inches higher than the placebo treatment. It is
likely that this improvement was due to both increased muscle force production performance and
decreased anterior knee pain. This study can not separate the underlying causes of the improved
performance, but can only note that they are related. Higher jumps require larger initiation
forces; placing increased compression forces on the patellofemoral joint. A decrease in pain
would allow the subject to improve their performance.
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Weekly Exercise
As part of the study protocol, subjects were asked to perform a home exercise program
(HEP). These exercises were part of a typical physical therapy regiment provided to patients
with PFPS. The use of closed chain exercises are an important component of the rehabilitation
process. Exercises like partial squats, have been reported by McConnell to prompt the highest
activation of the VMO (O’Sullivan, 2005).
During the course of the study, the subjects were asked to record the number of exercises
they were able to perform and their perceived pain (with 0 = no pain and 10 = excruciating pain).
They were also asked to increase the number of exercise repetitions as tolerated. There progress
was monitored by a licensed physical therapist.
The typical pattern for the subject who received Botox was an increase in the number
of repetitions and a decrease in pain from the beginning to the end of the study. The Placebo
subjects often had a similar trend in pain, but were unable to increase the number of repetitions
in a prescribed exercise. This has the potential to influence the long-term outcome of the
treatment.

64

Chapter 5: Conclusion

Since 1988, surgical lateral retinaculum release to relieve PFPS has been used with
success. Some believe the surgical release can treat both patella pain and some instability issues
when used as a treatment for PFPS. However, it is not only an invasive procedure in attempt to
release excessive lateral pull on the patella, but surgically, it can also result in potential serious
complications (Fox, 1993). Therefore, non-invasive treatments should be considered to treat
anterior knee pain.
The subject who received the Botox treatment experienced an improvement in
functional activities with decreased pain. These findings were consistent with a previous pilot
study performed in the same laboratory. The Placebo subjects showed less improvement or
experienced no change in symptoms.
As an alternative treatment, Botox offers a noninvasive treatment option. The direct
results of this study show perceived changes in pain during functional activities and an increase
in tolerance to exercise. Indirect results show a change in the balance of medial and lateral
muscle groups that may lead to long-term functional improvement. Balance of the knee extensor
musculature is critical for optimal patella movement during knee extension (Sanchis-Alfonso,
2006). Restoring the balance of the quadriceps complex should assist in improving normal knee
function.
Despite the fact that the research was limited by the small number of participants,
Botox was found to be safe and effective in treating anterior knee pain.
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Future Work
An ideal continuation of this study should include ten subjects with bilateral PFPS. The
double blind study should treat one limb with Botox and the contralateral limb with placebo
control. To address the study limitations, Botox treatment should be offered to those who
receive the placebo control as an incentive to participate in the study. This may offset the
number of inquiries who only desire the Botox treatment option.
Subjective questionnaires could be limited to include only LEFS, VAS, and possibly
AKPS. These metrics reported a clear difference between the two treatments. Objective tests
should continue to analyze the changes in kinetics and sEMG derivatives.
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APPENDIX A
1. Testing Script
Patient: ###
Date: / /
Start time:
End time:
Initiation: Biodex, monitor, and computer on
Computer: Motion monitor on: Joshua
motion monitor for research, Botox, data acquisition, EMG data, view toolbars new,
set-up edit capture parameters- 10 secs record, autosave and add name of file
Click: Capture, record activity
Position, velocity, force, EMG3(VL), EMG4(VM) [box #’s 3 and 4 labeled on the leads box]
Thank patient.
Patient warm-up 5 minutes 50 watts, 50 rpm. Leg positioning should be at 30° at end
stroke.

of pedal

Explain process and to quickly move to the seat to begin testing while warm.
Seat #__13.0___________
EMG placement- alcohol
leg extended : one handbreadth above patella (EMG3- lateralis)
Four fingers above medial angle of the patella (EMG 4- medialis)
Knee alignment
Strap in: leg arm number __. 3048 m 12 on arm
NOTE: the bottom of the ankle pad is located 1 inch from medial malleolus
ISOKINETIC 3 speed, knee, extension/flexion, concentric/concentric
set ROM range ___________ (should be close to 100-180 on Biodex screen
anatomically])
verify 90°, set reference range to 10 and then 90
limb weight (stop,enter,start to release leg)
limb weight__________________
autoscale, 70%, 5 reps, (1 set first for warm-up)
make sure speeds are set 1. 180°/s
and
180°/s
Do one test run and make sure the strap is tight enough
Change sets to three
COUNT STOPS
”ask patient to hit button when the red light hits at the end of each set

1.

[10-90
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2. 90°/s

180°/s

hit button
3. 45°/s

2.
3.

180°/s

hit button
5 reps and 3 sets – 60 sec rest
ISOMETRIC agonist
verify 90° & set reference to 30° or
set ROM @ 120 ±2 = 30 degree
limb weight (stop,enter,start to release leg)
limb weight__________________
autoscale, 70%, 5 reps, 3 sets
hit button after each set
60 sec rest
COUNT STOPS
set-up, standby, change ROM to 150 = 60 degrees
1.
limb weight ____________, autoscale, 70%, 5 reps, 3 sets
2.
setup, standby, change ROM to 90 degrees
3.
limb weight
____________, autoscale, 70%, 5 reps, 3 sets
ESC, ESC, GO to reports, check current date, evaluations, generate reports, F4, max average
for ft-lbs, hit F1 to print (see example of print out below). Calculate avg. for 150 (60°) patient
average _________________
hit done on motion monitor, set-up, capture parameters, change period to 50 seconds, change
file name
FATIGUE TESTING
verify 90°, set ROM at 150 (60° position), 40 seconds, 1 rep, at 80%, place average from
isometric testing at (60°)
limb weight_____________
Tell patient to aim at the bottom of the line and try to hold it for the 40 seconds
***patient doesn’t start 2nd set of fatigue until hour glass is off the motion monitor, Don’t go by
stop lights.***
Ask patient to hit button after 1 set.
COUNT STOPS
Repeat, stop
Repeat, stop
1.
2.
3.
To export: analyze, export, multiple users, user report
C:programfiles:innsport-motion monitor/ user/ Botox/ export
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2. Example Printout from the Biodex for Isometric Testing
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3. Sample of Week 12 Checklist
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4. Example of the End of the study Questionnaire

5. Subject Anthropometric data

Height (inches)

66

63

66

63

Weight (pounds)

128

116

128

105

Moment Arm (meters)

0.3048

0.2794

0.3048

0. 2794
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6. Anterior Knee Pain Scale Results
Session 1
Session 2
Session 3
Session 4
Change in Score

Botox ™
75
76
77
95
+20

Placebo 1
57
60
69
72
+15

Placebo 2
73
79
85
81
+8

Placebo 3
69
83
73
91
+22

7. Functional Index Questionnaire Results. Each question is scored from 0-2, unable to do no problem (Harrison, 1995).
Task
Session
Walking 1 mile

Botox ™
1,2,3,4
2,2,2,2

Placebo 1
1,2,3,4
1,1,2,2

Placebo 2
1,2,3,4
2,2,2,2

Placebo 3
1,2,3,4
1,1,1,1

Climbing 16 steps

1,2,1,2

1,1,1,2

1,1,1,2

1,2,2,2

Squatting

1,1,1,1

1,1,1,2

1,1,1,1

2,1,1,1

Kneeling

2,1,1,1

1,1,1,2

1,1,1,1

2,1,1,2

Prolonged sitting
knees bent
Climbing 32 steps

with 1,1,1,1

1,1,1,2

1,1,1,1

1,1,1,1

1,1,1,2

1,1,1,2

1,1,1,2

1,2,2,2

100 meter short run

1,2,2,2

1,1,1,2

2,2,2,2

1,1,2,2

Waking 1 city block

2,2,2,2

1,1,2,2

2,2,2,2

2,2,2,2

Total

11,12,11,13

8,8,10,16

11,11,11,13

11,11,12,13
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8. The Lower Extremity Functional Scale Results in percentage.
A score of 100% represents no difficulty with usual work, hobbies, bathing, walking,
putting on shoes, squatting, lifting objects from the floor, performing light activities,
getting in/out of car, walking 2 block to a mil, ascending/descending 10 stairs, standing
and sitting for 1 hour, running on uneven ground, making sharp turns while running fast,
hopping, and rolling out of bed.

Botox™

Placebo 1

Placebo 2

Placebo 3

Session 1

69

51

80

69

Session 2

87

63

79

71

Session 3

87

65

86

68

Session 4

91

59

81

85

9. Botox Subject: Work and Power results
Botox Subject
WORK

Power
180°

90°

45°

180°

90°

45°

1

5539

9181

14020

1

4171

3580

2736

4

1042

1562

3005

4

3438

3333

2696

6

2257

4085

5592

6

7365

6221

4073

12
Std
deviation

1297

3038

4024

12
Std
deviation

4809

5536

3260

1

98

175

436

1

269

155

85

4

178

332

989

4

617

651

945

6

179

373

293

6

585

598

145

12

221

205

589

12

513

449

589
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Placebo 1: Work and Power results
Placebo 1
WORK
1
4
6
12
Std
deviation
1
4
6
12

Power
180°
3834
120
103
38

90°
42
153
197
50

45°
989
191
219
55

883
17
17
5

313
6
22
1

436
12
28
6

1
4
6
12
Std
deviation
1
4
6
12

180°
8823
96
80
13

90°
71
60
76
9

45°
200
38
42
58

4460
13
13
18

155
5
9
3

85
2
5
21

180°

90°

45°

Placebo 2: Work and Power results

Placebo 2
WORK

Power
180°

90°

45°

1

2059

3657

5356

1

5465

5498

3829

4

2120

3075

4958

4

6750

5539

3577

6

1920

3733

5891

6

6833

5761

4125

12
Std
deviation

2773

5130

6216

12
Std
deviation

8983

7505

4282

1

333

337

759

1

1166

543

755

4

512

294

3511

4

1620

581

2394

6

279

526

310

6

1106

843

228

12

420

269

611

12

1546

352

261
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Placebo 3: Work and Power results

Placebo 3
WORK

Power
180°

90°

45°

180°

90°

45°

1

2120

3883

4803

1

7033

6424

3839

4

4297

5108

5250

4

13953

7887

3925

6

4066

5288

5119

6

14682

8397

3902

12
Std
deviation

3764

5321

5695

12
Std
deviation

14283

8949

4568

1

323

345

380

1

1180

539

305

4

133

378

272

4

561

546

165

6

276

274

826

6

953

388

727

12

95

246

319

12

913

518

382

10. Isometric torque Results in Nm for all study subjects.

Botox™
1

30°
26

60°
56

90°
59

Placebo 1
1

30°
30

60°
55

90°
49

4

57

78

87

4

45

59

57

6

43

73

73

6

40

61

59

12

37

77

75

12

41

64

61

Placebo 2
1

30°
19

60°
50

90°
60

Placebo 3
1

30°
45

60°
51

90°
54

4

51

39
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4

35

63

63

6

36

75

81

6

41

69

67

12

38

73

84

12

48

77

75

79
11. EMG ratios of VMO/VL
Botox™
1
4
6
12
Placebo 2
1
4
6
12

30°
0.91
NA
0.54
0.55
30°
0.44
0.33
0.37
0.33

60°
0.66
NA
0.52
0.60
60°
0.47
0.36
0.39
0.29

90°
0.54
NA
0.43
0.57
90°
0.41
0.34
0.30
0.36

Placebo 1
1
4
6
12
Placebo 3
1
4
6
12

30°
0.68
1.00
0.47
0.97
30°
0.68
0.50
0.66
0.76

60°
0.69
0.87
0.51
0.88
60°
0.61
NA
0.70
0.74

90°
0.80
0.82
0.45
0.79
90°
0.57
NA
0.85
0.62

12. Force plate results with flight time during a vertical jump (in seconds).

Week 1
Std Dev
Week 4
Std Dev
Week 6
Std Dev
Week 12
Std Dev

Botox™

Placebo 1

Placebo 2

Placebo 3

359

413

387

430

3.21
392

43.6
485

2.03
381

21.7

381
22.2

473

3.06
408

3.54
374
1.41
377

4.62
477

31.9
68.7
458

3.54
382

12.5

9.54
445

5.66

6.56

13. Summary of Botox Subjects’ weekly exercise results
Botox

Single Limb
Squat with
Squat
adduction
ITB stretch
week
reps / pain
reps / pain
reps/ pain
1
2/6
2/6
10 / 1
2
3/4
2/4
10 / 0
4
3/1
3/3
10 / 0
6
4/1
3/2
10 / 0
Weekly
exercise
8
5 / 1 report for Placebo
3/2 1
10 / 0
10
6/1
3/1
10 / 0
12
7/1
3/1
10 / 0

Side lying
Abduction
reps / pain
2/5
2/3
3/4
3/2
3/2
3/1
3/1

Straight leg
raise
reps / pain
2/7
2/5
3/5
3/4
3/2
3/1
3/2

Side raise
Adduction
reps / pain
2/4
2/4
3/4
3/4
3/2
3/1
3/1
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Placebo
1
week
1
2
4
6
8
10

Single
Limb Squat
reps / pain
2/7
3/5
3/1
3/3
2/0
3/3

Squat with
adduction
reps / pain
2/5
2/3
3/0
3/0
2/2
3/2

12

3/2

2/2

ITB stretch
reps/ pain
10 / 7
10 / 4
10 / 1
10 / 2
10 / 1
10 / 0

Side lying
Abduction
reps / pain
3/4
3/3
3/0
3/1
3/0
3/0

Straight leg
raise
reps / pain
3/6
3/5
3/3
3/2
3/0
3/0

Side raise
Adduction
reps / pain
3/5
3/4
3/1
3/1
3/0
3/0

10 / 0

3/1

3/2

3/2

ITB stretch
reps/ pain
10 / 2
10 / 2
10 / 2
10 / 2
10 / 2
10 / 2
10 / 2

Side lying
Abduction
reps / pain
2/5
2/5
2/5
2/5
2/4
2/3
2/2

Straight leg
raise
reps / pain
2/6
2 /6
2/5
2/4
2/4
2/3
2/2

Side raise
Adduction
reps / pain
2/5
2/7
2/4
2/4
2/4
2/3
2/2

ITB stretch
reps/ pain
10 / 10 / 10 / 10 / 10 / 10 / 10 / -

Side lying
Abduction
reps / pain
3/2
3/2
3/0
3/3
3/2
3/1
3/1

Straight leg
raise
reps / pain
3/5
3 /3
3/0
3/3
3/2
3/1
3/1

Side raise
Adduction
reps / pain
3/4
3/2
3/1
3/3
3/2
2/1
3/0

Weekly exercise report for Placebo 2
Placebo
2
week
1
2
4
6
8
10
12

Single
Limb Squat
reps / pain
2/4
2/3
2/ 2
3/3
3/1
3/2
3/2

Squat with
adduction
reps / pain
2/5
2/4
2/3
2/3
3/2
3/1
3/2

Weekly exercise report for Placebo 3
Placebo
3
week
1
2
4
6
8
10
12

Single
Limb Squat
reps / pain
3/1
3/0
3/0
3/3
3/1
3/1
3/0

Squat with
adduction
reps / pain
3/1
3/1
3/0
3/3
3/1
3/1
3/0
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APPENDIX B
CALIBRATION PLOTS
Position

D
egree°

100

y = -19.225x + 169.25
R2 = 0.9992

80
60
40
20
0
0

2

4

A

Volts

Velocity

6

8

10

y = 45.557x + 0.7484
R2 = 1

V
elocity(°/s)

200
100
0
-6

-4

-2

-100 0

2

4

6

-200
Volts

B
Torque

y = -182.3x - 14.05
R² = 0.999

Torque(N
m
)

400
300
200
100
0
-2

C

-1.5

-1

-0.5

0

Volts

Calibration plots for Biodex used in Matlab programs. Plots A, B, and C are the position,
velocity and torque respectively. Calibrations for force, position, and velocity were performed
using a simple oscilloscope, and voltmeter. These calibrations convert from a voltage source to a
real world degree, degree per second and torque (Nm) during testing sessions.
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APPENDIX C

A. Isokinetic Program
%--------------------------------------------% This program is designed to calibrate the
% pos, vel, and force data
% PEP 101007
%--------------------------------------------clear all
% clear all variables
close all
% close all windows and files
X=input('Select File to Run: ','s');
Y=load(X);
pos_V=Y(:,2);
vel_V=Y(:,3);
force_V=Y(:,4);
VL_emg=Y(:,5);
VMO_emg=Y(:,6);
file_len=length(pos_V);
RADIAN=3.14/180;
ma=input('Enter moment arm: ');
%ma=.34;
%--------------------------------------------% create arrays
%--------------------------------------------pos_RW=zeros(file_len,1);
vel_RW=zeros(file_len,1);
torque_RW=zeros(file_len,1);
work=zeros(file_len,1);
power=zeros(file_len,1);
segment=zeros(15,1);
%ave_vel=zeros(15,1);
%ave_work=zeros(15,1);
%ave_power=zeros(15,1);
%max_vel=zeros(15,1);
%--------------------------------------------% convert data
%--------------------------------------------for i=1:file_len
pos_RW(i)=(-19.225*pos_V(i))+169.25;
vel_RW(i)=(45.557 * vel_V(i))+0.7484;
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force_RW=-((-182.36*force_V(i))-14.053); % invert force values
torque_RW(i)=force_RW * ma;
work(i)=torque_RW(i)*(pos_RW(i)*RADIAN);
power(i)=torque_RW(i)*(vel_RW(i)*RADIAN);
end
%--------------------------------------------% find concentric segments of data
%--------------------------------------------k = 1;
loop_len = 5;
flag = 0;
stop = 0;
start=1;
%-------------------------------------------------------------------------% Plot results to confirm appropriate selection of data
%-------------------------------------------------------------------------figure('Name','Torque and EMG Data Window','NumberTitle','off')
% Plot results
subplot(3,1,1)
hold off
plot(pos_RW,'b')
title('Position')
ylabel('deg')
hold on
subplot(3,1,2)
hold off
plot(torque_RW,'b')
title('Torque')
ylabel('lbs-ft?')
hold on
subplot(3,1,3)
hold off
plot(vel_RW,'b')
title('Velocity')
ylabel('deg/sec')
hold on
%-------------------------------------------------------------------------% Continue processing data and 1st pass segment bounds.
%-------------------------------------------------------------------------while (stop == 0)
skip = 0;
for i=start:file_len-loop_len
if (i == file_len-loop_len)
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stop = 1;
end
flag = 0;
if (skip == 0)
for j=1:loop_len-1
if (vel_RW(i+j) > vel_RW(i+j-1) && vel_RW(i+j) > 10)
flag = flag + 1;
end
end
if (flag == loop_len-1) %found a concentric segment
for m=i+j:-1:1
if (vel_RW(m) <= 0 && flag == loop_len-1)
segment(k) = m;
%vel_RW(m);
%flag
k=k+1;
flag = -1;
end
end
end
if (flag == -1) %found beginning concentric, now wait till end to search for next
for n=segment(k-1)+1:file_len
if (vel_RW(n) <= 0 && flag == -1)
segment(k) = n;
k=k+1;
flag = 0;
start=n;
skip = 1;
end
if (n >= file_len) % stop if no end of segment found
flag = 0;
k=k-1;
end
if (flag == 0)
break
end
end
end
if (skip == 1)
break
end
end
end
number = (k-1)/2 %display number of segment
segment (1:number*2,1) %display segment boundaries
%--------------------------------------------------------------------------
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% Plot the 1st pass segment bounds.
%-------------------------------------------------------------------------for i=1:number*2
x = [segment(i) segment(i)]; plot(x,ylim,'r')
% ylim = axis limits
end
%-------------------------------------------------------------------------% Improve segment bounds estimates. Use the middle 50 points of each
% velocity segment to determine the base standard deviation. Set a
% decision threshold at 2x that value. Starting from the middle of a
% segment and progressing outward in both directions, compute the standard
% deviation and when it exceeds the threshold, the new segment bounds are
% stored (replacing the old values).
%-------------------------------------------------------------------------for i=1:2:number*2
half_len = int16((segment(i+1) - segment(i))/2-25); % center +/- 25 pts
for j=half_len:-1:1
start = segment(i)+j-1;
stop = segment(i+1)-j-1;
stdev = std(vel_RW(start:stop));
if (j == half_len)
threshold = stdev *2;
% threshold at 2 x stdev
end
if (stdev > threshold)
segment(i) = start;
% set new start value
segment(i+1) = stop;
% set new stop value
break;
end
end
end
%-------------------------------------------------------------------------% Plot the 2nd pass segment bounds (in green).
%-------------------------------------------------------------------------for i=1:number*2
x = [segment(i) segment(i)]; plot(x,ylim,'g')
% ylim = axis limits
end
segment (1:number*2,1) %display segment boundaries
%-------------------------------------------------------------------------% calculate maximum velocity, average velocity, work and power for
% concentric knee extension
%-------------------------------------------------------------------------k=1;
for i=1:2:number*2
ave_work(k) = mean(work(segment(i):segment(i+1)));
ave_power(k) = mean(power(segment(i):segment(i+1)));
ave_vel(k) = mean(vel_RW(segment(i):segment(i+1)));
max_vel(k) = max(vel_RW(segment(i):segment(i+1)));
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% for j=segment(i):segment(i+1)
% ave_work(k) = ave_work(k) + work(j);
%
ave_power(k) = ave_power(k) + power(j);
% ave_vel(k) = ave_vel(k) + vel_RW(j);
%
if (vel_RW(j) > max_vel(k))
%
max_vel(k) = vel_RW(j);
% end
% end
% ave_vel(k) = ave_vel(k) / (segment(i+1)-segment(i));
% ave_work(k) = ave_work(k) / (segment(i+1)-segment(i));
% ave_power(k) = ave_power(k) / (segment(i+1)-segment(i));
k=k+1;
end
t_work = 0;
t_power = 0;
for i=1:number
t_work = ave_work(i);
t_power = ave_power(i);
end
t_work = t_work / number;
t_power = t_power / number;
%--------------------------------------------% save data
%--------------------------------------------out=strcat(X,'.cal');
export=[pos_RW vel_RW torque_RW work power];
double(export);
save(out, 'export', '-ascii', '-tabs');
out2=strcat(X,'.ave');
%export=[number t_work t_power];
%double(export);
%save(out2, 'export', '-ascii', '-tabs');
%CHANGE BACK TO COLUMAR DATA OUTPUT -- PEP 021308
export=[max_vel(1:number)'
ave_vel(1:number)'
ave_power(1:number)'];
%export=[max_vel ave_vel ave_work ave_power];
double(export);
save(out2, 'export', '-ascii', '-tabs');
B. Isometric Program
%-------------------------------------------------------------------------% ISOMETRIC.M -% This program is designed to calibrate the position, velocity, and torque
% data. It determines the location of the isometric segment in the data
% stream and computes the max, min, and average of that segment. It also

ave_work(1:number)'
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% computes the RMS EMG for the VMO and VL muscles. All data is restored in
% text file format.
% PEP 020408
%-------------------------------------------------------------------------clear all
% clear all variables
close all
% close all windows and files
X=input('Select File to Run: ','s');
Y=load(X);
pos_V=Y(:,2);
vel_V=Y(:,3);
force_V=Y(:,4);
VL_emg=Y(:,5);
VMO_emg=Y(:,6);
file_len=length(pos_V);
RADIAN=3.14/180;
ma=input('Enter moment arm: ');
%ma=.34;
uthresh = input('Enter data start position: ');
if (isempty (uthresh))
% set variable to 1 if no value entered
uthresh = 1;
end
%-------------------------------------------------------------------------% create arrays
%-------------------------------------------------------------------------pos_RW=zeros(file_len,1);
vel_RW=zeros(file_len,1);
torque_RW=zeros(file_len,1);
work=zeros(file_len,1);
power=zeros(file_len,1);
segment=zeros(15,1);
ave_vel=zeros(15,1);
ave_work=zeros(15,1);
ave_power=zeros(15,1);
max_vel=zeros(15,1);
%-------------------------------------------------------------------------% convert data
%-------------------------------------------------------------------------for i=1:file_len
pos_RW(i)=(-19.225*pos_V(i))+169.25-180;
vel_RW(i)=(45.557 * vel_V(i))+0.7484;
force_RW=-((-182.36*force_V(i))-14.053); % invert force values
torque_RW(i)=force_RW * ma;
work(i)=torque_RW(i)*(pos_RW(i)*RADIAN);
power(i)=torque_RW(i)*(vel_RW(i)*RADIAN);
end
%--------------------------------------------------------------------------
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% determine baseline mean and stdv in first 250ms of torque data -- the
% controlling variable is baseline_size and is initially set to 25
%-------------------------------------------------------------------------baseline_size = 250;
average = mean(torque_RW(1:baseline_size));
standard_dev = std(torque_RW(1:baseline_size));
%-------------------------------------------------------------------------% find isometric segment -- Note: use max torque value as condition to
% help find end of segment
%-------------------------------------------------------------------------flag = 0;
file_max = max(torque_RW);
iso_start = 0;
iso_stop = 0;
threshold = average + (4 * standard_dev);
scnt = 500; % start value must exceed threshold for 0.5s (sampled @ 1000Hz)
if (uthresh > 1)
baseline_size = uthresh; % set start of search to user defined position
end
for i=baseline_size:file_len
if (torque_RW(i) >= file_max)
flag = 1;
end
if (iso_start == 0 && torque_RW(i) > threshold)
%
iso_start = i;
cnt = 0;
for j=i+1:file_len
% look for consistently met threshold
if (torque_RW(j) > threshold)
cnt = cnt + 1;
else
break;
end
if (cnt >= scnt)
iso_start = i;
break;
end
end
end
if (iso_stop == 0 && iso_start > 0 && torque_RW(i) < threshold && flag == 1)
iso_stop = i;
end
end
if iso_stop == 0
iso_stop = file_len;
% set end to EOF if none found
end
iso_time = (iso_stop - iso_start) / 1000;
% to be saved
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% Define figure and start plot
figure('Name','Torque and EMG Data Window','NumberTitle','off')
subplot(3,1,1)
hold off
plot(torque_RW,'b')
title('Torque')
ylabel('Nm')
hold on
x = [iso_start iso_start]; plot(x,ylim,'r') % ylim provides axis limits
x = [iso_stop iso_stop]; plot(x,ylim,'r') % ylim provides axis limits
%-------------------------------------------------------------------------% compute isometric torque max, min, and average values
%-------------------------------------------------------------------------max_torque = max(torque_RW(iso_start:iso_stop));
% to be saved
min_torque = min(torque_RW(iso_start:iso_stop));
% to be saved
ave_torque = mean(torque_RW(iso_start:iso_stop));
% to be saved
%-------------------------------------------------------------------------% EMG processing
%-------------------------------------------------------------------------% Determine EMG baseline (for same amount of data used in torque baseline %above
VL_average = mean(VL_emg(1:baseline_size));
VMO_average = mean(VMO_emg(1:baseline_size));
% Subtract baseline from raw EMG data and compute RMS data
for i=1:file_len
VL_emg_BL = VL_emg(i) - VL_average;
VMO_emg_BL = VMO_emg(i) - VMO_average
VL_rms(i) = sqrt(VL_emg_BL * VL_emg_BL);
VMO_rms(i) = sqrt(VMO_emg_BL * VMO_emg_BL);
end
% Use time constant (TAU) to smooth the data
tau = 250;
% 25ms equivalent at 1000Hz sampling rate
half_tau = floor(tau / 2);
% round down
for i=half_tau+1:file_len-half_tau
VL_filt(i) = mean(VL_rms(i-half_tau:i+half_tau));
VMO_filt(i) = mean(VMO_rms(i-half_tau:i+half_tau));
end
for i=1:half_tau
% fill in the ends
VL_filt(i) = VL_filt(half_tau+1);
VMO_filt(i) = VMO_filt(half_tau+1);
end
for i=file_len-half_tau+1:file_len
% fill in the ends
VL_filt(i) = VL_filt(file_len-half_tau);
VMO_filt(i) = VMO_filt(file_len-half_tau);
end
% Determine average RMS during isometric hold
ave_VL = mean(VL_filt(iso_start:iso_stop));
% to be saved
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ave_VMO = mean(VMO_filt(iso_start:iso_stop));
% to be saved
% Plot results
subplot(3,1,2)
hold off
plot(VL_rms,'b')
title('VL')
ylabel('v')
hold on
plot(VL_filt,'r')
subplot(3,1,3)
hold off
plot(VMO_rms,'b')
title('VMO')
ylabel('v')
hold on
plot(VMO_filt,'r')
%pause;
%-------------------------------------------------------------------------% save data (results and processed data)
%-------------------------------------------------------------------------fid = fopen(strcat(X,'.emg'),'w');
fprintf(fid,'%s\n',X);
fprintf(fid,'iso time = \t%.3f\t sec\n',iso_time);
fprintf(fid,'start = \t%.3f\t sec\n',iso_start/1000);
fprintf(fid,'stop = \t%.3f\t sec\n\n',iso_stop/1000);
fprintf(fid,'ave torque = \t%.3f\t Nm\n',ave_torque);
fprintf(fid,'max_torque = \t%.3f\t Nm\n',max_torque);
fprintf(fid,'min_torque = \t%.3f\t Nm\n\n',min_torque);
fprintf(fid,'ave VL = \t%.3f\n',ave_VL);
fprintf(fid,'ave VMO = \t%.3f\n',ave_VMO);
fclose(fid);
out=strcat(X,'.emg_data.xls');
export=[transpose(VL_rms(1:file_len))
transpose(VL_filt(1:file_len))
transpose(VMO_rms(1:file_len)) transpose(VMO_filt(1:file_len))];
double(export);
save(out, 'export', '-ascii', '-tabs');

C. Fatigue Program
% FATIGUE (botox)
clear all
% clear all variables
close all
% close all windows and files
sampling_rate = 1000;
% set to 1000Hz
interval = 1 / sampling_rate;
X=input('Select File to Run: ','s');
Y=load(X);
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pos_V=Y(:,2);
vel_V=Y(:,3);
force_V=Y(:,4);
VL_emg=Y(:,5);
VMO_emg=Y(:,6);
file_len=length(pos_V);
% REMOVE OFFSET FROM DATA
VL_emg = VL_emg - mean(VL_emg);
VMO_emg = VMO_emg - mean(VMO_emg);
% END REMOVE OFFSET
%-------------------------------------------------------------------------% Find start (t1) and stop (t2) of the usable EMG data based on force
% data.
%-------------------------------------------------------------------------t1 = 0;
t2 = 0;
threshold = max(force_V) * .5;
% threshold @ 50 percent
for i=1:file_len
if (t1 == 0 && force_V(i) >= threshold)
% find start
t1 = i;
end
if (t1 > 0 && t2 == 0 && force_V(i) < threshold) % find stop
if (i > t1+5000)
% added to reduce false stops
t2 = i;
end
end
end
if (t2 == 0)
% define stop as EOF if none found
t2 = file_len;
end
%-------------------------------------------------------------------------% Plot raw data.
%-------------------------------------------------------------------------close all;
figure('Name','RAW EMG Data Window','NumberTitle','off')
% CREATE TIME ARRAY FOR PLOTTING
cnt=1;
while cnt <= file_len
xtime(cnt) = (cnt-1)*interval;
cnt = cnt + 1;
end
% PLOT RAW DATA
hold off
plot(xtime,VL_emg,'b')
str = sprintf('Raw Data (VL)');
title(str)
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xlabel('time')
ylabel('volts')
hold on
% overplot start and stop
x = [t1*interval t1*interval]; plot(x,ylim,'r') % ylim = axis limits
x = [t2*interval t2*interval]; plot(x,ylim,'r') % ylim = axis limits
pause(3);
hold off
%-------------------------------------------------------------------------% Compute median freq for segments of EMG using and overlap method
%-------------------------------------------------------------------------fft_len = 512;
count=1;
start = t1;
stop = t1+fft_len-1;
while stop < t2
Raw = VL_emg(start:stop);
% NEW FFT WAY!!!
%array_len = length(Y);
%half_len = int16(array_len / 2);
Y=fft(Raw);
YY=Y.*conj(Y)/length(Y);
f=1000*(0:length(Y)/2)/length(Y);
figure('Name','Data','NumberTitle','off')
subplot(2,1,1)
plot(xtime,VL_emg,'b')
str = sprintf('Raw Data (VL)');
title(str)
xlabel('time')
ylabel('volts')
hold on
istart = start*interval
istop = stop*interval
x = [istart istart]; plot(x,ylim,'r');
% ylim = axis limits
x = [istop istop]; plot(x,ylim,'r');
% ylim = axis limits
hold off
subplot(2,1,2)
plot(f(1:int16(length(Y)/2)),YY(1:int16(length(Y)/2)),'b')
hold on;
% END NEW FFT WAY
% COMPUTE MEDIAN FREQUENCY
cnt = length(Y)/2+1;
sum = 0;
for i=1:cnt
sum = sum + (1 * YY(i));
end
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half_sum = sum/2; sum = 0;
i=1;
while sum <= half_sum
sum = sum + (1 * YY(i));
median_freq(count) = f(i);
i = i + 1;
end
count;
median_freq(count);
x = [median_freq(count) median_freq(count)]; plot(x,ylim,'r');
% ylim = axis limits
str = sprintf('FFT (VL) median freq = %.2f',median_freq(count));
title(str)
xlabel('freq')
ylabel('amplitude')
hold off;
% END COMPUTE MEDIAN FREQUENCY
count=count+1;
pause(2);
close all;
clf;
j = stop+1 - (fft_len/2);
start = j;
stop = j+fft_len-1;
end
%-------------------------------------------------------------------------% Plot median frequencies
%-------------------------------------------------------------------------close all;
figure('Name','Fatigue Analysis','NumberTitle','off')
% CREATE TIME ARRAY FOR PLOTTING
cnt=1;
clear xaxis;
while cnt < count
xaxis(cnt) = (cnt-1);
cnt = cnt + 1;
end
% PLOT RAW DATA
plot(xaxis,median_freq,'b')
str = sprintf('Median Frequency');
title(str)
xlabel('count')
ylabel('Hz')
pause(3);
%-------------------------------------------------------------------------% Open a data storage file & store median frequency
%--------------------------------------------------------------------------
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out=strcat(X,'.fat');
export=[median_freq]';
double(export);
save(out, 'export', '-ascii', '-tabs');
close all;
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APPENDIX D

A. Patellofemoral Pain Study Pre-Study Questionnaire
Name
Age:
Do you have:
Knee pain: Yes No
If yes is your knee pain on the Right or Left
Rate your knee pain on a scale of 0 – 10 (0 no pain, 10 the worst pain you can imagine) ______
Did your pain begin as the result of trauma/injury or did it begin gradually
Have you ever had knee surgery on this knee: Yes No
Has your patellar (kneecap) ever dislocated Yes No
Describe your knee pain in relation to your kneecap ie behind, below, to the inside or outside of
the kneecap
Do you have this pain while (put an X next to each one that you answer yes to)
_____ prolonged sitting,
_____ climbing stairs,
_____ squatting,
_____ running,
_____ kneeling,
_____ hopping,
_____ jumping.
How long have you had this knee pain _______
Have you ever had an allergic reaction to Botulinum toxin A (Botox) injection Yes No
Please list all known allergies:
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B. Patellofemoral Pain Pre-Study Evaluation

C. Patellofemoral Pain Prior Perceived pain
Date: __________________________
Subject Number: ____________
No Pain___________________________________________________________ Worst Pain
For the Usual amount of pain you have had today
Indicate on the line where the pain is in relation to the two extremes
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D. First preliminary Patellofemoral Pain study visit
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E. LEFS Form

F. Patellofemoral Pain VAS for ascending, descending, and jumping
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G. Patellofemoral Pain VAS for great and usual Pain
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